- Home
- BRNS vs BLRX Comparison
BRNS vs BLRX Comparison
Compare BRNS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- BLRX
- Stock Information
- Founded
- BRNS 2016
- BLRX 2003
- Country
- BRNS United Kingdom
- BLRX Israel
- Employees
- BRNS N/A
- BLRX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- BLRX Health Care
- Exchange
- BRNS Nasdaq
- BLRX Nasdaq
- Market Cap
- BRNS 36.0M
- BLRX 15.3M
- IPO Year
- BRNS 2021
- BLRX 2011
- Fundamental
- Price
- BRNS $0.95
- BLRX $4.43
- Analyst Decision
- BRNS Strong Buy
- BLRX Strong Buy
- Analyst Count
- BRNS 1
- BLRX 2
- Target Price
- BRNS $3.00
- BLRX $19.00
- AVG Volume (30 Days)
- BRNS 13.5K
- BLRX 132.4K
- Earning Date
- BRNS 08-07-2025
- BLRX 08-14-2025
- Dividend Yield
- BRNS N/A
- BLRX N/A
- EPS Growth
- BRNS N/A
- BLRX N/A
- EPS
- BRNS N/A
- BLRX N/A
- Revenue
- BRNS $14,969,000.00
- BLRX $22,340,000.00
- Revenue This Year
- BRNS N/A
- BLRX N/A
- Revenue Next Year
- BRNS N/A
- BLRX N/A
- P/E Ratio
- BRNS N/A
- BLRX N/A
- Revenue Growth
- BRNS 4381.74
- BLRX 91.68
- 52 Week Low
- BRNS $0.64
- BLRX $2.30
- 52 Week High
- BRNS $1.58
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- BRNS 57.55
- BLRX 49.46
- Support Level
- BRNS $0.90
- BLRX $4.05
- Resistance Level
- BRNS $1.05
- BLRX $4.64
- Average True Range (ATR)
- BRNS 0.06
- BLRX 0.34
- MACD
- BRNS 0.01
- BLRX -0.07
- Stochastic Oscillator
- BRNS 71.96
- BLRX 68.18
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.